Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis.
Zhonghan ZhangYaxiong ZhangGang ChenShaodong HongYunpeng YangWenfeng FangFan LuoXi ChenYuxiang MaYuanyuan ZhaoJianhua ZhanCong XueXue HouTing ZhouShuxiang MaFangfang GaoYan HuangLikun ChenNingning ZhouHongyun ZhaoLi ZhangPublished in: The oncologist (2018)
According to the results of this study, olanzapine-based triple antiemetic regimens were superior in both overall and delayed-phase nausea control when compared with various neurokinin-1 receptor antagonists-based triple regimens in patients with highly emetogenic chemotherapy (HEC). Olanzapine-based triplet was outstanding in terms of nausea control and drug price. For cancer patients with HEC, especially those suffering from delayed-phase nausea, olanzapine-based triple regimens should be an optional antiemetic choice.